855291-54-2 Usage
Chemical structure
A complex structure that includes a bicyclic ring system with a nitrogen atom, an indole group, and a pyridazine group linked to the bicyclic structure through an oxygen atom.
Stereochemistry
(3R)-, indicating the specific arrangement of atoms around the chiral center.
Potential pharmaceutical applications
Due to its unique structure and the presence of heterocyclic rings, which are often found in bioactive molecules.
Biological activity
The specific biological activity and potential uses of 1-Azabicyclo[2.2.2]octane, 3-[[6-(1H-indol-5-yl)-3-pyridazinyl]oxy]-,
(3R)- would need to be further studied and determined.
Molecular weight
Approximately 250.34 g/mol (calculated from the molecular formula)
Functional groups
The compound contains several functional groups, including an indole, a pyridazine, and an ether (oxy) group.
Chirality
The presence of the (3R)stereochemistry indicates that the compound has a chiral center, which may have implications for its biological activity and potential pharmaceutical applications.
Solubility
The solubility of 1-Azabicyclo[2.2.2]octane, 3-[[6-(1H-indol-5-yl)-3-pyridazinyl]oxy]-,
(3R)- would depend on its specific physical and chemical properties, which would need to be determined experimentally.
Stability
The stability of 1-Azabicyclo[2.2.2]octane, 3-[[6-(1H-indol-5-yl)-3-pyridazinyl]oxy]-,
(3R)- under various conditions (e.g., temperature, pH, light exposure) would also need to be studied to assess its suitability for pharmaceutical applications.
Please note that this list is based on the information provided and may not be exhaustive. Further research and experimentation would be necessary to fully characterize 1-Azabicyclo[2.2.2]octane, 3-[[6-(1H-indol-5-yl)-3-pyridazinyl]oxy]-,
(3R)- and determine its potential applications.
Check Digit Verification of cas no
The CAS Registry Mumber 855291-54-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,5,2,9 and 1 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 855291-54:
(8*8)+(7*5)+(6*5)+(5*2)+(4*9)+(3*1)+(2*5)+(1*4)=192
192 % 10 = 2
So 855291-54-2 is a valid CAS Registry Number.
855291-54-2Relevant academic research and scientific papers
FUSED BICYCLOHETEROCYCLE SUBSTITUTED QUINUCLIDINE DERIVATIVES
-
Page/Page column 59, (2010/11/08)
Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N+-O-; X is O, S, -NH-, and -N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by a7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.
Fused bicycloheterocycle substituted quinuclidine derivatives
-
Page/Page column 22-23, (2010/02/12)
Compounds of formula (I) wherein n is 0, 1, or 2; X is O, S, —NH—, and —N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.
Fused bicycloheterocycle substituted quinuclidine derivatives
-
Page/Page column 26, (2010/02/12)
Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N+—O?; X is O, S, —NH—, and —N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.
Fused bicycloheterocycle substituted quinuclidine derivatives
-
, (2008/06/13)
Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N+—O—; X is O, S, —NH—, and —N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.
